Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platformFiled IND in ...
The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.
A new study from Cornell University has strengthened the case for using a specific group of molecules—known as microRNAs—as ...
Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.
Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...
Stocktwits on MSN3d
Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-HighShares of Portage Biotech Inc. more than doubled in after-hours trading on Thursday as the company reported promising ...
Leveraging the power of AI and machine learning technologies, researchers developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy.
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...
Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback